Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Jul 5;38(1):290.
doi: 10.1186/s13046-019-1302-0.

Targeting mutant p53 in cancer: the latest insights

Silvia Di Agostino  1 , Giulia Fontemaggi  2 , Sabrina Strano  2 , Giovanni Blandino  2 , Gabriella D'Orazi  3   4
Affiliations
Editorial

Targeting mutant p53 in cancer: the latest insights

Silvia Di Agostino et al. J Exp Clin Cancer Res. .

Abstract

This commentary wishes to highlight the latest discoveries in the mutant p53 field that have been discussed in the 8th p53 Mutant Workshop 2019, held in Lyon. TP53 mutant (mutp53) proteins are involved in the pathogenesis of most human cancers. Mutp53 proteins not only lose wild-typ53 function but, in some circumstances, may acquire novel oncogenic functions, namely gain-of-function (GOF), which lead to aberrant cell proliferation, chemoresistance, disruption of tissue architecture, migration, invasion and metastasis. Decoding the TP53 mutational spectrum and mutp53 interaction with additional transcription factors will therefore help to developing and testing novel and hopefully more efficient combinatorial therapeutic approaches.

Keywords: Cancer-associated fibroblasts; Exosomes; Li-Fraumeni; Mutant p53 reactivation; Small molecules; miRNA; p53.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Schematic representation of the ongoing research in the mutp53 field. The Lyon’s map as a framework to show the crucial hub of mutp53 at the crossroads of many interventions aimed at understanding its mutational status, and the way to reactivate it for diagnostic and therapeutic purposes
See this image and copyright information in PMC

References

    1. Mantovani F, Collavin LDS. G: mutant p53 as a guardian of the cancer cells. Cell Death Differ. 2019;26:199–212. doi: 10.1038/s41418-018-0246-9. - DOI - PMC - PubMed
    1. D'Orazi G, Cirone M. Mutant p53 and cellular stress pathways: a criminal alliance that promotes cancer progression. Cancers (Basel) 2019;11:E614. doi: 10.3390/cancers11050614. - DOI - PMC - PubMed
    1. Guha T, Malkin D. Inherited TP53 mutations and the li-Fraumeni syndrome. Cold Spring Harb Perspect Med. 2017;3:7. - PMC - PubMed
    1. Ballinger ML, Best A, Mail PL, Khincha PP, Loud JT, Peters JA, et al. Baseline surveillance in li-Fraumeni syndrome using whole-body magnetic resonance imaging: a meta-analysis. JAMA Oncol. 2017;3:1634–1639. doi: 10.1001/jamaoncol.2017.1968. - DOI - PMC - PubMed
    1. Greathouse KL, White JR, Vargas AJ, Bliskovsky VV, Beck JA, von Muhlinen N, et al. Interaction between the microbiome and TP53 in human lung cancer. Genome Biol. 2018;19:123. doi: 10.1186/s13059-018-1501-6. - DOI - PMC - PubMed

Publication types

Substances